Dynamic Technology Lab Private Ltd Purchases New Stake in Certara, Inc. $CERT

Key Points

• Dynamic Technology Lab Private Ltd acquired a new stake in Certara, Inc., purchasing 30,021 shares valued at approximately $297,000 in the first quarter.
• Following the acquisition, institutional investors now own 73.96% of Certara's stock, indicating strong institutional confidence in the company.
• Certara recently reported quarterly earnings, missing the consensus EPS estimate, but showing a 12.1% annual revenue increase, with a market cap of $1.81 billion.

Dynamic Technology Lab Private Ltd purchased a new stake in shares of Certara, Inc. (NASDAQ:CERT - Free Report) in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 30,021 shares of the company's stock, valued at approximately $297,000.

Several other institutional investors have also added to or reduced their stakes in CERT. Versant Capital Management Inc raised its holdings in Certara by 218.8% in the 1st quarter. Versant Capital Management Inc now owns 2,719 shares of the company's stock worth $27,000 after purchasing an additional 1,866 shares in the last quarter. Caitong International Asset Management Co. Ltd bought a new position in Certara in the 1st quarter worth $31,000. AlphaQuest LLC bought a new position in Certara in the 1st quarter worth $39,000. Quarry LP bought a new position in Certara in the 1st quarter worth $98,000. Finally, Associated Banc Corp bought a new position in Certara in the 1st quarter worth $101,000. 73.96% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, insider Leif E. Pedersen sold 51,224 shares of the stock in a transaction dated Tuesday, September 9th. The shares were sold at an average price of $10.92, for a total transaction of $559,366.08. Following the sale, the insider directly owned 73,979 shares of the company's stock, valued at approximately $807,850.68. This represents a 40.91% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 2.33% of the company's stock.

Wall Street Analyst Weigh In

Several research analysts have commented on the stock. Zacks Research upgraded shares of Certara from a "strong sell" rating to a "hold" rating in a report on Friday, September 5th. Morgan Stanley assumed coverage on shares of Certara in a report on Thursday, July 3rd. They issued an "equal weight" rating and a $16.00 price objective for the company. UBS Group decreased their price objective on shares of Certara from $17.50 to $15.00 and set a "buy" rating for the company in a report on Thursday, August 7th. Finally, KeyCorp decreased their price objective on shares of Certara from $18.00 to $15.00 and set an "overweight" rating for the company in a report on Monday, July 14th. Five analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $15.14.

Certara Stock Up 3.3%

Shares of Certara stock opened at $11.28 on Friday. The company has a debt-to-equity ratio of 0.27, a current ratio of 2.16 and a quick ratio of 2.16. The company has a 50-day moving average of $10.73 and a 200 day moving average of $11.28. The firm has a market cap of $1.81 billion, a price-to-earnings ratio of 225.65 and a beta of 1.43. Certara, Inc. has a 1 year low of $8.64 and a 1 year high of $15.69.

Certara (NASDAQ:CERT - Get Free Report) last issued its quarterly earnings results on Wednesday, August 6th. The company reported $0.07 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.10 by ($0.03). Certara had a return on equity of 5.11% and a net margin of 1.97%.The business had revenue of $104.57 million during the quarter, compared to the consensus estimate of $104.14 million. During the same quarter in the previous year, the business earned $0.07 earnings per share. The firm's revenue was up 12.1% compared to the same quarter last year. As a group, sell-side analysts anticipate that Certara, Inc. will post 0.28 earnings per share for the current fiscal year.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.

Want to see what other hedge funds are holding CERT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Certara, Inc. (NASDAQ:CERT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.